T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XHR
1726
Xenia Hotels & Resorts
XHR
$1.77B
| $1.92M | ﹤0.01% |
106,025
-4,288
| -4% | -$75.7K |
|
1727
Rogers Corp
ROG
$2.54B
| $1.92M | ﹤0.01% |
7,022
-895
| -11% | -$218K |
|
1728
Park National Corp
PRK
$3.74B
| $1.91M | ﹤0.01% |
13,912
-251
| -2% | -$33.4K |
|
1729
United Bankshares
UBSI
$6.69B
| $1.91M | ﹤0.01% |
52,609
-835
| -2% | -$30.7K |
|
1730
Axos Financial
AX
$5.82B
| $1.91M | ﹤0.01% |
34,079
-3,732
| -10% | -$209K |
|
1731
Leggett & Platt
LEG
$1.32B
| $1.9M | ﹤0.01% |
46,250
-172,275
| -79% | -$7.48M |
|
1732
Avnet
AVT
$7.86B
| $1.9M | ﹤0.01% |
46,164
-6,066
| -12% | -$234K |
|
1733
Integra LifeSciences
IART
$1.42B
| $1.9M | ﹤0.01% |
28,351
-1,887
| -6% | -$128K |
|
1734
Werner Enterprises
WERN
$2.32B
| $1.9M | ﹤0.01% |
39,842
-551
| -1% | -$25.2K |
|
1735
U-Haul Holding Co
UHAL
$14.4B
| $1.9M | ﹤0.01% |
26,140
-1,470
| -5% | -$106K |
|
1736
Carlyle Group
CG
$17.6B
| $1.89M | ﹤0.01% |
34,491
-2,734
| -7% | -$149K |
|
|
ITCI
1737
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.89M | ﹤0.01% |
36,189
-4,333
| -11% | -$182K |
|
1738
Tronox
TROX
$945M
| $1.89M | ﹤0.01% |
78,432
-1,152
| -1% | -$27.6K |
|
|
TMHC
1739
DELISTED
Taylor Morrison
TMHC
| $1.88M | ﹤0.01% |
53,691
-4,631
| -8% | -$145K |
|
|
VG
1740
DELISTED
Vonage Holdings Corporation
VG
| $1.87M | ﹤0.01% |
90,024
-5,989
| -6% | -$109K |
|
1741
Progyny
PGNY
$2.01B
| $1.87M | ﹤0.01% |
37,094
+16,798
| +83% | +$940K |
|
1742
Hecla Mining
HL
$12.4B
| $1.85M | ﹤0.01% |
355,459
-9,641
| -3% | -$53.9K |
|
1743
iShares MSCI EAFE Growth ETF
EFG
$17.3B
| $1.85M | ﹤0.01% |
16,802
| – | – |
|
1744
SITE Centers
SITC
$156M
| $1.85M | ﹤0.01% |
150,049
-3,937
| -3% | -$49.4K |
|
1745
Navient
NAVI
$856M
| $1.84M | ﹤0.01% |
86,628
-3,109
| -3% | -$62.9K |
|
1746
First Advantage
FA
$3.71B
| $1.83M | ﹤0.01% |
+96,173
| New | +$1.85M |
|
1747
Medifast
MED
$128M
| $1.83M | ﹤0.01% |
8,737
-215
| -2% | -$44.4K |
|
1748
Independence Realty Trust
IRT
$4B
| $1.83M | ﹤0.01% |
70,822
-3,464
| -5% | -$82K |
|
1749
STAAR Surgical
STAA
$1.29B
| $1.83M | ﹤0.01% |
20,022
-4,285
| -18% | -$460K |
|
1750
Renasant Corp
RNST
$3.97B
| $1.83M | ﹤0.01% |
48,149
-2,186
| -4% | -$82.8K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.